Search Results for: Routine

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors.

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors.

Tuberculosis Literature
Publication date: Nov 17, 2025 Although testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with IL-17 or IL-23 inhibitors, evidence for this practice ... Read more